Skip to content

Study · Animal study (in vivo) · mouse and rat · 1998

4 results

A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.

Jelovac N, Sikirić P, Rucman R, Petek M, Perović D, Konjevoda P, Marović A, Seiwerth S, Grabarević Z, Sumajstorcić J, Dodig G, Perić J

Biological psychiatry1 Apr 1998Cited by 32 (Europe PMC)

PMID9547930 (opens in a new tab)DOI10.1016/s0006-3223(97)00277-1 (opens in a new tab)PepBankPUB-09547930
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given amphetamine, BPC‑157 markedly attenuated stereotypic behavior.

    In plain wordsIn rats given amphetamine, BPC‑157 strongly reduced repetitive stereotyped behavior.

    Peptide
    BPC-157
    Outcome
    DecreaseAmphetamine-induced stereotypy
    Study

    ratn: not reported in source

    amphetamine stereotypy and acoustic startle
    Comparator
    Amphetamine control
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    10 µg/kg (prophylactic) or 10 ng/kg (therapeutic) · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    There was a marked attenuation of stereotypic behavior
    1 context sentence
    Summary · context
    We first investigated the effect of pentadecapeptide BPC 157 on stereotypy and acoustic startle response in rats, given as either a prophylactic (10 micrograms/kg i.p.) or therapeutic (10 ng/kg i.p.) regimen, with the dopamine indirect agonist amphetamine (10 mg/kg i.p.).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given amphetamine, BPC‑157 markedly attenuated the acoustic startle response.

    In plain wordsIn rats given amphetamine, BPC‑157 strongly reduced the startle response to sound.

    Peptide
    BPC-157
    Outcome
    DecreaseAmphetamine-induced acoustic startle response
    Study

    ratn: not reported in source

    amphetamine stereotypy and acoustic startle
    Comparator
    Amphetamine control
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    10 µg/kg (prophylactic) or 10 ng/kg (therapeutic) · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    and acoustic startle response.
    1 context sentence
    Summary · context
    We first investigated the effect of pentadecapeptide BPC 157 on stereotypy and acoustic startle response in rats, given as either a prophylactic (10 micrograms/kg i.p.) or therapeutic (10 ng/kg i.p.) regimen, with the dopamine indirect agonist amphetamine (10 mg/kg i.p.).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given amphetamine, BPC‑157 given at the time of maximum excitability reversed the amphetamine-induced behavior.

    In plain wordsIn rats given amphetamine, BPC‑157 given at peak excitability reversed the behavior.

    Peptide
    BPC-157
    Outcome
    DecreaseReversal of amphetamine-induced excitability when given at its peak
    Study

    ratn: not reported in source

    amphetamine stereotypy and acoustic startle
    Comparator
    Amphetamine control
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    When the medication was given at the time of maximum amphetamine-induced excitability, there was a reversal of this behavior.
    1 context sentence
    Summary · context
    We first investigated the effect of pentadecapeptide BPC 157 on stereotypy and acoustic startle response in rats, given as either a prophylactic (10 micrograms/kg i.p.) or therapeutic (10 ng/kg i.p.) regimen, with the dopamine indirect agonist amphetamine (10 mg/kg i.p.).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice pretreated with haloperidol, BPC‑157 coadministered with haloperidol almost completely reversed supersensitivity to amphetamine.

    In plain wordsIn mice, BPC‑157 given with haloperidol almost fully reversed an increased reaction to amphetamine.

    Peptide
    BPC-157
    Outcome
    DecreaseHaloperidol-induced supersensitivity to amphetamine (climbing behavior)
    Study

    mousen: not reported in source

    haloperidol pretreatment then amphetamine challenge
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    An almost complete reversal was noted when pentadecapeptide was coadministered with haloperidol.
    1 context sentence
    Summary · context
    A further focus was on the effect of this pentadecapeptide on increased climbing behavior in mice pretreated with the dopamine antagonist haloperidol (5.0 mg/kg i.p.), and subsequently treated with amphetamine (20 mg/kg i.p. challenge 1, 2, 4, and 10 days after haloperidol pretreatment).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.